One Lab's Journey to Close the Interpretation Gap in Oncology Reporting

Evidence-based interpretation of oncogenic variants represents one of the most demanding and time-consuming tasks carried out by clinical laboratories today. The volume of emerging clinical evidence,and the multiplication of evidence sources across fragmented platforms, combined with the need fortimely and accurate reporting, places considerable pressure on laboratory workflows and the professionals who lead them.

In this webinar, Dr. Sara Allegrini, Head of Molecular Pathology at TomaLab, one of the largest genetic laboratories in Italy, examines how the integration of OncoPortal™ Knowledge Base within SOPHiADDM™ has reshaped their approach to oncology variant interpretation. The session draws on Dr.Allegrini's real-world experience to trace the laboratory's workflow evolution, from their previous use of OncoPortal™ Plus as a standalone module to the adoption of a fully integrated solution.

Dr. Allegrini will share first-hand insights into the challenges of evidence-based interpretation at scale,the criteria that guided TomaLab's adoption of OncoPortal™ Knowledge Base, and the impact observedon reporting efficiency and interpretation confidence. The session will also illustrate the value of the platform through concrete case examples, including rare alterations and complex findings where accessto curated, current evidence proved decisive.

At the conclusion of this session, participants will be able to:

• Identify the key real-world challenges in evidence-based oncogenic variant interpretation and recognize workflow factors that affect reporting efficiency and accuracy
• Analyze the impact of centralizing multiple sources of evidence directly into a single interpretation workflow and platform
• Investigate the technological and organizational steps required for laboratories to adopt evidence-rich variant interpretation at scale

Presenter

Dr. Sara Allegrini, Molecular Biologist, Leading the Somatic Molecular Diagnostics Unit at a specialized pathology laboratory

Dr. Sara Allegrini is a molecular biologist and expert in precision oncology, currently leading the Somatic Molecular Diagnostics Unit at a specialized pathology laboratory. With over a decade of experience in molecular diagnostics and cancer genomics, she plays a key role in integrating advanced technologies such as next-generation sequencing into routine clinical practice.

She holds a PhD in Molecular Medicine and a specialization in Clinical Pathology, complemented by a recent advanced Master’s degree in Molecular Pathology and Molecular Tumor Boards. Her expertise spans next-generation sequencing, molecular oncology, and precision medicine, with a strong focus on the interpretation of somatic variants in cancer. Her work focuses on the clinical interpretation of somatic variants and their application in personalized cancer treatment.

She has a strong background in translational research, bridging the gap between laboratory innovation and patient care. She is passionate about advancing precision medicine and improving diagnostic strategies in oncology.